NLS Pharmaceutics Ltd. (NASDAQ:NLSP) executed a reverse stock split and merged with Kadimastem Ltd., forming NewcelX Ltd. to trade under the ticker "NCEL".The merger aims to enhance focus on developing therapies for central nervous system disorders.Post-merger, NLSP's stock price reflects an increase, with a current market capitalization of approximately $2.4 million and a trading volume of 30.3 million shares.NLS Pharmaceutics Ltd. (NASDAQ:NLSP), a Swiss clinical-stage biopharmaceutical company, has underg ...